



Email not displaying correctly?
[View it in your browser](#)

Contact us
+44 345 080 9000
medicaldevices@bsigroup.com



Regulatory review

Your monthly medical device update
May 2022

Featured in this Newsletter

- Clinical Series toolkit
- Hybrid audit - webinar and video
- IVDR Date of Application
- Medicinal Dossier
- Events for your calendar
- Using standards to demonstrate conformity

Clinical Masterclass Toolkit

● Discover our new Clinical Toolkit

- Webinars
- Whitepapers
- View on Demand
- Clinical Guidance

Our Clinical Masterclass series of webinars is now completed, and we hope you enjoyed the series. These five insightful webinars focussed on various aspects of the MDR, from looking at postmarket clinical follow-up, to helping you with your medical device software and when a clinical evaluation is required.

[View the full Series](#)

Following the success of the Clinical Masterclass Series, we've also launched the Clinical Toolkit. The new comprehensive Clinical toolkit will hopefully make your journey of understanding to the MDR smoother. The toolkit will focus on the Clinical Masterclass series of webinars as well as:

- On-demand videos
- White papers
- Internal and external guidance documents

[To access the Toolkit click here](#)

Hybrid audit - webinar and video

Join us for our next webinar on hybrid audits – the new way of working post pandemic. We will share our audit lessons learnt during the pandemic as well as how best to plan for future audits. We will focus on unannounced audits and maintaining regulatory compliance, whilst also focussing on our sustainability commitment.



Hear from Linda Moon, Global Quality & Accreditation Manager, Regulatory Services, as she talks about why we are using hybrid audits and how they can help improve better client service levels. Linda will also be joined by subject matter expert Dr. Yoann Buisson, GQA Technical Manager, Regulatory Services.

Choose from one of the two sessions on **Wednesday May 25:**

09:00 – 10:00 BST - [Register here](#)

16:00 – 17:00 BST - [Register here](#)

[Watch the Hybrid audit video](#)

IVDR Date of Application arrives

The IVDR EU 2017/746 entered into force in May 2017 with a five-year transition period.

Manufacturers have the duration of this period to update their Technical Documentation to meet the requirements and comply with the Regulation before the **Date of Application on 26 May 2022.**



To keep up to date with the timelines of the transition from IVDD to IVDR follow the weekly updates on the [BSI Medical Devices LinkedIn page](#) and the [BSI website](#).

New BSI Medicinal dossier guidance

For devices which incorporate an ancillary medicinal substance and fall under Rule 14 of EU 2017/745 (MDR), the quality, safety and usefulness of the substance shall be verified by analogy with the methods specified in Annex I to Directive 2001/83/EC (the Medicinal Products Directive). Annex IX, 5.2(a) of the MDR states the notified body should seek a scientific opinion from one of the competent authorities designated by the Member States in accordance with Directive 2001/83/EC or from the EMA, on the quality and safety of the substance including the benefit or risk of the incorporation of the substance into the device.

Download our guidance for devices which incorporate an ancillary medicinal substance and fall under Rule 14 of EU 2017/745 (MDR).

[Find out more on our website.](#)

Devices incorporating ancillary medicinal substances

Medicinal dossier guidance

For devices which incorporate an ancillary medicinal substance and fall under Rule 14 of EU 2017/745 (MDR)

For devices which incorporate an ancillary medicinal substance and fall under Rule 14 of EU 2017/745 (MDR), the quality, safety and usefulness of the substance shall be verified by analogy with the methods specified in Annex I to Directive 2001/83/EC (the Medicinal Products Directive). Annex IX, 5.2(a) of the MDR states the notified body should seek a scientific opinion from one of the competent authorities designated by the Member States in accordance with Directive 2001/83/EC or from the EMA, on the quality and safety of the substance including the benefit or risk of the incorporation of the substance into the device.

Annex II, Section 6.2 (a) states the documentation shall identify the source of that substance and contain the data of the tests conducted to assess its safety, quality and usefulness, taking account of the intended purpose of the device.

In order to perform their assessment, the Medicines Competent Authorities (CA) prefer the documentation to follow the Common Technical Documentation (CTD) format. CTD is the format used for pharmaceutical assessment of medicinal products and use of this format facilitates the CA review.

bsi. Inspiring trust for a more resilient world.

[Download our guidance](#)

Using standards to demonstrate conformity | New white paper available for download



One important characteristic of standards is that they are voluntary – there is no obligation to apply them or comply with them, except in those few cases where their application is directly required by regulations. However, the application of standards in the medical devices sector has undoubtedly been accelerated by their use to support regulation by providing a voluntary means to demonstrate conformity with regulatory requirements.

[Download whitepaper](#)

Events for your calendar

Register for the MedTech Summit 2022 and find out more about our latest [Events](#) and [Conferences](#).



bsi.



[Unsubscribe](#)

Inspiring trust for a more resilient world.